Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
293.9 EUR | -0.24% |
|
-3.70% | -7.52% |
Jul. 01 | West Pharmaceutical Services, Inc.(NYSE:WST) added to Russell Midcap Value Index | CI |
Jul. 01 | West Pharmaceutical Services, Inc.(NYSE:WST) added to Russell 3000 Value Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.82 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.52% | 23.5B | - | ||
-5.50% | 181B | C+ | ||
-5.79% | 99.52B | C | ||
-6.59% | 65.82B | A | ||
-8.38% | 45.21B | B- | ||
+8.42% | 43.85B | B- | ||
+10.10% | 42.17B | B+ | ||
+10.97% | 28.75B | B | ||
+18.89% | 25.39B | A- | ||
-11.25% | 22.22B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- WST Stock
- WPS Stock
- Ratings West Pharmaceutical Services, Inc.